

CSD/BSE&NSE/2022-2023
September 7, 2022

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/ Madam,

Sub: Clarification /Confirmation on news item appearing in “Media/Publication”

Ref: Your email L/SURV/ONL/RV/IJ/ (2022-2023)/16 dated September 7, 2022

Ref: Your letter no. NSE/CM/Surveillance/12264 dated September 7, 2022

We refer to your email/letter cited under reference on the subject received through email, asking us clarify on the news item that appeared today in the “Website-www.moneycontrol.com” dated September 07, 2022 captioned “Suven Pharma on the block, in talks with PE, strategic firms for control deal.”

- a) We wish to inform you that the Company as of now is not aware of such negotiation and thus considers the said news item as merely speculative and factually incorrect.
- b) The Company does not comment on speculations in news media. We follow the highest standards of corporate governance, and the Company is conscious of its disclosure obligations under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”). Please be assured that the Company will always make a disclosure if and when the same is required under the Listing Regulations. We wanted to reiterate that as on date, there has been no development which requires a disclosure under the Listing Regulations.
- c) The material impact of this article on the Company. NIL

We request you to take the above on record.

Thanking you,
Yours faithfully,
For Suven Pharmaceuticals Limited

K. Hanumantha Rao
Company Secretary

Suven Pharmaceuticals Limited